Seres Therapeutics (MCRB) Posts Q2 Loss of $1.45/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Seres Therapeutics (MCRB) Posts Q2 Loss of $1.45/Share

Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update

August 6, 2015 7:01 AM EDT

- Phase 2 study initiated for lead microbiome therapeutic SER-109 for prevention of recurrent Clostridium difficile infection (CDI) in adults
- FDA Breakthrough Therapy Designation received for SER-109
- Successfully completed initial public offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today reported financial results and provided a business update for the second quarter ended June 30, 2015.... More